Peter Attia

So if someone came along and said, look, we're going to do all the things, we're going to rub curcumin on people's testicles and do all the things that are anecdotally supposed to help.

And it takes median survival from 11 months to 27 months.

Wow, that's huge.

Oh, and by the way, it's going to reduce the burden of seizures and it's going to reduce the catastrophic debilitating side effects of this tumor and its therapy.

I mean, it's going to become the standard of care, but the trial has to be done.

The trial has to be done.

It can't be these sort of one-off kludgy, like off in the corner little

nonsense trials that aren't getting attention.

So why is that?

Is GBM the wrong model then?

Because you need a win.

Yeah.

You got to demonstrate a win.

Should the first one be pancreatic adeno?

You have far more patients...

Life expectancy is a little bit longer, but it's equally fatal, meaning metastatic or advanced pancreatic cancer is uniformly fatal.

Should we be using that as a model where, of course, look, all cancers are heterogeneous, but it might be that GBM is even more so.

And it's also heavily impacted by the radiation.

The radiation then completely changes it.

Virtually all of these patients are going to need radiation, which